Drug and dietary supplement manufacturers should respond broadly as well as specifically to regulatory inspectors’ findings of quality control problems and be sure they understand the potential impact on their business from each finding, an industry consultant advised during a recent conference.
Firms also should avoid “absolute chaos” and last-minute changes as they prepare corrective action and prevention action (CAPA) plans and...





